[1]
|
中国产业调研网.中国干细胞医疗市场现状调研与发展前景分析报告(2018-2025年)[EB/OL].http://www. cir. cn/R_ YiYaoBaoJian/20/GanXiBaoYiLiaoFaZhanXian ZhuangFenXiQianJingYuCe.html. |
[2]
|
裴雪涛.干细胞产业化发展现状、瓶颈及展望[EB/OL].https://www.360zhyx.com/home-research-index-rid-64539.shtml. |
[3]
|
Takahashi K, Yamanaka S.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors[J].Cell, 2006, 126:663-676. doi: 10.1016/j.cell.2006.07.024 |
[4]
|
Newsha H, Mohammad P, Parvaneh F, et al.Stem Cell Banking in Iran[M].New York: Springer, 2014: 123-141. |
[5]
|
Torsvik A, Rosland GV, Svendsen A, et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field ontrack[J]. Cancer Res, 2010, 70:6393-6396. doi: 10.1158/0008-5472.CAN-10-1305 |
[6]
|
Hughes P, Marshall D, Reid Y, et al. The costs of using unauthenticated, over-passaged cell lines:how much more data do we need?[J]. Biotechniques, 2007, 43:575-583. doi: 10.2144/000112598 |
[7]
|
Masters JR. False cell lines: the problem and the solution[J]. Cytotechnology, 2002, 39:69-74. doi: 10.1023/A:1022908930937 |
[8]
|
Wrigley JD, McCall EJ, Bannaghan CL, et al.Cell banking for pharmaceuticalresearch[J].Drug Discov Today, 2014, 19:1518-1529. doi: 10.1016/j.drudis.2014.05.006 |
[9]
|
Kimmelman J, Heslop HE, Sugarman J, et al.New ISSCR guidelines: clinical translation of stem cellresearch[J].Lancet, 2016, 387:1979-1981. doi: 10.1016/S0140-6736(16)30390-7 |
[10]
|
国务院.人类遗传资源管理暂行办法[EB/OL].http://www.gene.gov.cn/news/7643806.html. |
[11]
|
国家卫生计生委, 国家食品药品监管总局.干细胞临床研究管理办法(试行)[EB/OL].http://www.nhfpc.gov.cn/ qjjys/s3581/201508/28635ef99c5743e294f45e8b29c72309.shtml. |
[12]
|
中国工程电子设计院.洁净厂房设计规范GB50073-2013[EB/OL].http://www.jhgc-kwt.com/mingci/950.html. |
[13]
|
国家食品药品监督管理局.关于贯彻实施《药品生产质量管理规范(2010年修订)》的通知[EB/OL].http://samr.cfda.gov.cn/WS01/CL0844/59017.html. |
[14]
|
郜恒骏, 周学迅, 张小燕, 等.ISBER最佳实践2018[J].中国医药生物技术, 2018, 13(增刊):1-54. |
[15]
|
王太平, 徐国彤, 周琪, 等.国际干细胞研究学会《干细胞临床转化指南》[J].生命科学, 2009, 21:747-756. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=smkx200905026 |
[16]
|
祝贺, 郝捷, 周琪, 等.临床级干细胞库及干细胞制剂[J].生命科学, 2016, 28:895-901. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=smkx201608013 |
[17]
|
International Stem Cell Banking Initiative.Consensus guid-ance for banking and supply of humanembryonic stem cell lines for research purposes[J].Stem Cell Rev, 2009, 5:301-314. doi: 10.1007/s12015-009-9085-x |
[18]
|
国家卫生计生委办公厅, 食品药品监管总局办公厅.干细胞制剂质量控制及临床前研究指导原则(试行)[EB/OL].https: //bbs.iiyi.com/thread-2619912-1.html. |
[19]
|
Fisher M.ISBT 128—a new international standard for labelling and data management blood transfusion[J]. Transfus Sci, 1995, 16:249-254. doi: 10.1016/0955-3886(95)00030-2 |
[20]
|
Froud SJ.Cell Bank Preparation and Characterization[M].New Jersey: Humana Press, 1999: 99-115. |
[21]
|
Sun C, Yue J, He N, et al.Fundamental Principles of Stem Cell Banking[J]. Adv Exp Med Biol, 2016, 951:31-45. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=35677b54d4777aa3b38d8eb897178c2e |
[22]
|
国家药典委员会.中华人民共和国药典[M].北京: 中国医药科技出版社, 2012: 附录190-191. |
[23]
|
FACT-JACIE.International Standards for Cellular Therapy Product Collection, Processing, and Administration for Hematopoietic Cellular Therapies[EB/OL]. https: //www.docin.com/p-1003220446.html& dpage=1& key. |
[24]
|
赵庆辉, 周红梅, 穆会玲, 等.干细胞资源库及信息管理系统的标准化建设[J].转化医学杂志, 2018, 7:17-19. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyxzz201801005 |